DaVita Inc. (DVA)
| Market Cap | 12.75B +14.7% |
| Revenue (ttm) | 13.84B +6.7% |
| Net Income | 781.42M -9.1% |
| EPS | 10.74 +6.2% |
| Shares Out | 64.20M |
| PE Ratio | 19.11 |
| Forward PE | 12.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,127,110 |
| Open | 196.60 |
| Previous Close | 196.26 |
| Day's Range | 193.85 - 199.27 |
| 52-Week Range | 101.00 - 199.27 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 187.83 (-5.45%) |
| Earnings Date | May 5, 2026 |
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In... [Read more]
Financial Performance
In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for DVA stock is "Buy." The 12-month stock price target is $187.83, which is a decrease of -5.45% from the latest price.
News
DaVita price target raised to $205 from $158 at Truist
Truist raised the firm’s price target on DaVita (DVA) to $205 from $158 and keeps a Hold rating on the shares. The firm is raising its assumed multiple after the
DaVita price target raised to $235 from $190 at UBS
UBS analyst AJ Rice raised the firm’s price target on DaVita (DVA) to $235 from $190 and keeps a Buy rating on the shares.
DaVita price target raised to $194 from $158 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on DaVita (DVA) to $194 from $158 and keeps an Equal Weight rating on the shares. The firm updated the company’s
DaVita upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Pito Chickering upgraded DaVita (DVA) to Buy from Hold with a price target of $220, up from $126, following the Q1 report. The firm sees “two shining
Early notable gainers among liquid option names on May 6th
Notable gainers among liquid option names this morning include DaVita (DVA) $189.02 +31.98, Super Micro (SMCI) $33.07 +5.24, Advanced Micro Devices (AMD) $418.78 +63.52, International Flavors (IFF) $8...
DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference
DENVER, May 6, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will parti...
DaVita lifts annual profit forecast on strong demand for dialysis services
DaVita on Tuesday raised its forecast for annual adjusted profit after beating Wall Street estimates for first-quarter results, betting on steady demand for its kidney dialysis services.
DaVita Earnings Call Transcript: Q1 2026
First quarter results exceeded expectations, driven by higher treatment volume, improved productivity, and technology investments. Guidance for adjusted operating income and EPS was raised, with additional volume growth expected from competitor clinic closures.
DaVita reports Q1 EPS $2.87, consensus $2.33
Reports Q1 revenue $3.42B, consensus $3.36B. “DaVita’s (DVA) foundation is clinical excellence, driven by operating rigor that produces durable results,” said Javier Rodriguez, CEO of DaVita Inc. “We ...
DaVita sees FY26 adjusted EPS $14.10-$15.20, consensus $14.12
Previous guidance was $13.60-$15.00.
DaVita Inc. 1st Quarter 2026 Results
DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2026. "DaVita's foundation is clinical excellence, driven by opera...
Honeywell Announces Board of Directors for Honeywell Aerospace
Directors bring compelling mix of aerospace and defense expertise, leadership experience, and financial and capital markets backgrounds Honeywell spin-off of Honeywell Aerospace expected to be complet...
DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call
DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. E...
DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy an...
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global dev...
DaVita Transcript: TD Cowen 46th Annual Health Care Conference
2026 OI growth is projected above the low end of long-term targets, driven by U.S. dialysis, international, and IKC segments. Margin maintenance, cost controls, and IT investments are key, while APTC expiration and clinical programs will shape future mix and volume. Double-digit EPS growth and disciplined capital deployment remain priorities.
DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference
DENVER, Feb. 24, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will par...
DaVita price target raised to $158 from $128 at Truist
Truist raised the firm’s price target on DaVita (DVA) to $158 from $128 and keeps a Hold rating on the shares. The firm is adjusting its model to reflect the
DaVita price target raised to $144 from $133 at TD Cowen
TD Cowen raised the firm’s price target on DaVita (DVA) to $144 from $133 and keeps a Hold rating on the shares. The firm updated its model following Q4 results.
DaVita price target raised to $190 from $186 at UBS
UBS raised the firm’s price target on DaVita (DVA) to $190 from $186 and keeps a Buy rating on the shares. 2026 guidance implies roughly 3% adjusted operating income growth
DaVita Stock (DVA) Soars 20% as Financial Results Beat Wall Street Estimates
Warren Buffett is the company’s largest shareholder.
TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings
The AI trade is helping Teradyne (TER), with Diane King Hall pointing to the company's latest earnings as a signal of forward strength. Outside of tech, she notes DaVita's (DVA) earnings beat and guid...